EORTC Probabilistic Risk Model
Tumor Characteristics
Awaiting Data
Complete all six tumor characteristics to generate EORTC probability estimates.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
When to Use the EORTC Risk Tables
Predicting recurrence risk after TURBT for newly diagnosed NMIBC (Ta, T1, or CIS) to guide surveillance frequency (cystoscopy every 3 vs 6 vs 12 months)
Predicting progression risk to muscle-invasive bladder cancer (MIBC, T2+) to guide adjuvant intravesical therapy (BCG vs chemotherapy) vs early radical cystectomy
Stratifying patients in clinical trials of NMIBC (entry criteria based on EORTC risk groups)
Shared decision-making with patients about treatment intensity (e.g., high-risk patient may choose early cystectomy rather than repeated BCG)
Determining need for restaging TURBT at 4–6 weeks (recommended for high-risk EORTC progression score ≥ 8)
Counseling patients about compliance (high-risk recurrence predicts need for multiple cystoscopies and intravesical treatments)
Post-BCG failure management: EORTC risk table progression score helps decide between repeat BCG (low progression risk) vs early cystectomy (high progression risk)
EORTC vs CUETO (Spanish) vs EAU Risk Groups — Comparative Performance
| Risk Tool | Variables Included | Derivation Cohort (N) | C-Index for Recurrence | C-Index for Progression | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| EORTC (2006) | Tumor number (3 levels), tumor size (<3 vs ≥3 cm), prior recurrence rate (3 levels), T category (Ta vs T1), CIS (yes/no), Grade (G1–3) | 2,596 (7 EORTC trials, all received TURBT + intravesical chemotherapy (not BCG) or TURBT alone) | 0.61–0.64 | 0.71–0.74 | Most widely used, validated in multiple external cohorts (Asia, Europe, US), simple to calculate, 1-year and 5-year predictions, helps select adjuvant BCG vs chemotherapy | Overestimates recurrence risk (especially in modern cohorts with better TURBT quality, photodynamic diagnosis), does not include BCG maintenance in derivation (all chemotherapy), Grade based on WHO 1973 (not 2004/2016), no TVC (variant histology) |
| CUETO (Spanish, 2009) | Tumor number (single vs multiple), tumor size (<3 vs ≥3 cm), prior recurrence (yes/no), T category (Ta vs T1), CIS (yes/no), Grade (G1–3), age (<70 vs ≥70) | 1,062 (CUETO trials, all received TURBT + BCG maintenance) | 0.61–0.63 | 0.68–0.71 | Derived in BCG-treated patients (more relevant to modern practice), includes age (older age predicts worse progression), better calibration for BCG-treated cohorts | Less widely used, no risk tables for no-BCG patients, still uses WHO 1973 Grade, not updated for WHO 2004/2016 |
| EAU Risk Groups (2024 update) | Combines EORTC and CUETO plus additional variables (TVC, lymphovascular invasion, prostatic urethra involvement, completeness of TURBT) | Expert consensus (not derived from single cohort) | Not applicable (guideline, not predictive model) | Not applicable | Simpler group assignment (low, intermediate, high, very high), incorporates modern histology (WHO 2004/2016 Grade Group, TVC, LVI), guides BCG use and cystectomy timing | Subjective (not point-based), less granular than EORTC, not validated as a predictive model (consensus-based) |
Modern Validation — EORTC Overestimates Recurrence but Still Valid for Progression
Multiple external validations (2010–2024, n > 15,000 patients) show EORTC tables overestimate recurrence risk by 10–30% in modern cohorts (due to better TURBT quality, photodynamic diagnosis, immediate post-op intravesical chemotherapy, and improved risk-stratified treatment). However, progression prediction remains accurate (c-index 0.70–0.74). Clinical implication: For recurrence, use EORTC to identify relative risk (low vs high) but not absolute percentages; for progression, EORTC absolute percentages are reliable. Example: EORTC predicts 5-year recurrence 60% for high-risk patient; actual with modern TURBT + immediate chemo + BCG may be 40–50%, but still high-risk relative to low-risk patient with 20% actual. Do NOT deny patient BCG because EORTC recurrence overestimated; BCG reduces recurrence by 50% regardless.
Related Scores in Practice
In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Eau Nmibc Risk Groups or the Tnm Bladder Cancer to formulate a comprehensive care plan.
Last Comprehensive Review: 2026